Robert F. Kennedy Jr., nominated by President-elect Donald Trump to lead the Department of Health and Human Services, shared his views on the burgeoning sector of weight-loss medications Thursday. Speaking with CNBC’s Jim Cramer at the New York Stock Exchange, Kennedy emphasized the importance of healthy living as a primary approach to weight management.

Kennedy, known for his critical perspective on the pharmaceutical industry, underscored that lifestyle changes should be the initial response to obesity rather than immediately turning to GLP-1 drugs. His comments come at a time when Wall Street is closely monitoring his potential impact on health policy, following his nomination by Trump last month.

GLP-1 medications, including Novo Nordisk’s Wegovy and Ozempic, as well as Eli Lilly’s Zepbound and Mounjaro, have seen a surge in popularity, sparking a competitive race among pharmaceutical companies. The investor community has been particularly bullish on Novo and Eli Lilly (NYSE:LLY), with the latter becoming the world’s most valuable health-care company. Forecasts suggest that the market for these drugs could reach or exceed $100 billion by 2030.

Kennedy’s confirmation by the Senate is pending, and his position on GLP-1 drugs has been a focal point for investors trying to anticipate future health policies. His presence at the New York Stock Exchange, alongside other cabinet nominees, was part of the ceremonial opening bell event led by Trump on Thursday, marking the beginning of the trading session.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.